Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel
- 26 May 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 130 (7), 1706-1713
- https://doi.org/10.1002/ijc.26180
Abstract
The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks. Data from these patients who received at least one cycle of preoperative FLOT followed by surgery were prospectively collected in three German centres. Outcome analyses were conducted and tumour samples were evaluated for pathological remission by a central pathologist. A total of 46 patients were included in this analysis. All patients had clinical T3‐ and/or N+‐stages and 11 (23.9%) had distant metastases (M1). After a median of 4 (range 2–8) preoperative cycles, 8 of 46 patients (17.4%) achieved a pCR. The pCR rate was highest in tumours of intestinal type histology (30.8%) and in those located in the oesophagogastric junction (30.4%) and lowest in patients with diffuse/mixed type tumours (0%) or tumours located in the stomach (4.3%; p < 0.05 for both comparisons). Patients with pCR had 100% probability of overall and disease‐free survival (DFS) during the observation period, which was significantly higher (p = 0.037 and p = 0.009, respectively) than the survival probability in patients without pCR. In conclusion, treatment intensification using FLOT was associated with significant pCR rates in patients with oesophagogastric cancer. The distribution of pCR appeared to be significantly different according to histological type and location of the tumours.Keywords
This publication has 34 references indexed in Scilit:
- [18F]‐fluorodeoxyglucose‐positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancerJournal of Surgical Oncology, 2010
- Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapyBritish Journal of Cancer, 2010
- Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual fociBritish Journal of Surgery, 2010
- A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinomaBritish Journal of Cancer, 2009
- Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)Gastric Cancer, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1Journal of Clinical Oncology, 2003